TY - JOUR
T1 - Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database
AU - Sokka, T
AU - Kautiainen, H
AU - Pincus, T
AU - Toloza, S
AU - da Rocha Castelar Pinheiro, G
AU - Lazovskis, J
AU - Hetland, Merete Lund
AU - Peets, T
AU - Immonen, K
AU - Maillefert, J F
AU - Drosos, A A
AU - Alten, R
AU - Pohl, C
AU - Rojkovich, B
AU - Bresnihan, B
AU - Minnock, P
AU - Cazzato, M
AU - Bombardieri, S
AU - Rexhepi, S
AU - Rexhepi, M
AU - Andersone, D
AU - Stropuviene, S
AU - Huisman, M
AU - Sierakowski, S
AU - Karateev, D
AU - Skakic, V
AU - Naranjo, A
AU - Baecklund, E
AU - Henrohn, D
AU - Gogus, F
AU - Badsha, H
AU - Mofti, A
AU - Taylor, P
AU - McClinton, C
AU - Yazici, Y
PY - 2009/11
Y1 - 2009/11
N2 - OBJECTIVE: To analyse associations between the clinical status of patients with rheumatoid arthritis (RA) and the gross domestic product (GDP) of their resident country.METHODS: The Quantitative Standard Monitoring of Patients with Rheumatoid Arthritis (QUEST-RA) cohort includes clinical and questionnaire data from 6004 patients who were seen in usual care at 70 rheumatology clinics in 25 countries as of April 2008, including 18 European countries. Demographic variables, clinical characteristics, RA disease activity measures, including the disease activity score in 28 joints (DAS28), and treatment-related variables were analysed according to GDP per capita, including 14 "high GDP" countries with GDP per capita greater than US$24,000 and 11 "low GDP" countries with GDP per capita less than US$11,000.RESULTS: Disease activity DAS28 ranged between 3.1 and 6.0 among the 25 countries and was significantly associated with GDP (r = -0.78, 95% CI -0.56 to -0.90, r(2) = 61%). Disease activity levels differed substantially between "high GDP" and "low GDP" countries at much greater levels than according to whether patients were currently taking or not taking methotrexate, prednisone and/or biological agents.CONCLUSIONS: The clinical status of patients with RA was correlated significantly with GDP among 25 mostly European countries according to all disease measures, associated only modestly with the current use of antirheumatic medications. The burden of arthritis appears substantially greater in "low GDP" than in "high GDP" countries. These findings may alert healthcare professionals and designers of health policy towards improving the clinical status of patients with RA in all countries.
AB - OBJECTIVE: To analyse associations between the clinical status of patients with rheumatoid arthritis (RA) and the gross domestic product (GDP) of their resident country.METHODS: The Quantitative Standard Monitoring of Patients with Rheumatoid Arthritis (QUEST-RA) cohort includes clinical and questionnaire data from 6004 patients who were seen in usual care at 70 rheumatology clinics in 25 countries as of April 2008, including 18 European countries. Demographic variables, clinical characteristics, RA disease activity measures, including the disease activity score in 28 joints (DAS28), and treatment-related variables were analysed according to GDP per capita, including 14 "high GDP" countries with GDP per capita greater than US$24,000 and 11 "low GDP" countries with GDP per capita less than US$11,000.RESULTS: Disease activity DAS28 ranged between 3.1 and 6.0 among the 25 countries and was significantly associated with GDP (r = -0.78, 95% CI -0.56 to -0.90, r(2) = 61%). Disease activity levels differed substantially between "high GDP" and "low GDP" countries at much greater levels than according to whether patients were currently taking or not taking methotrexate, prednisone and/or biological agents.CONCLUSIONS: The clinical status of patients with RA was correlated significantly with GDP among 25 mostly European countries according to all disease measures, associated only modestly with the current use of antirheumatic medications. The burden of arthritis appears substantially greater in "low GDP" than in "high GDP" countries. These findings may alert healthcare professionals and designers of health policy towards improving the clinical status of patients with RA in all countries.
KW - Antirheumatic Agents
KW - Arthritis, Rheumatoid
KW - Cost of Illness
KW - Epidemiologic Methods
KW - Female
KW - Health Status Disparities
KW - Humans
KW - Male
KW - Middle Aged
KW - Socioeconomic Factors
KW - World Health
U2 - 10.1136/ard.2009.109983
DO - 10.1136/ard.2009.109983
M3 - Journal article
C2 - 19643759
SN - 0003-4967
VL - 68
SP - 1666
EP - 1672
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 11
ER -